ProductHighlights:
ThistargetedRNAsequencingpanelisacost-effectivesolutiontodetectgenefusionsinmultiplecancertypes,regardlessoforigin.Covering507fusion-associatedgenes,asingleassayenablesresearcherstoassessmostknowncancer-relatedfusionsinblood,bonemarrow,andFFPEsamples,withthepowertoidentifynovelfusiongenepartners.
- Industry-validatedcontentforacomprehensiveviewofcancer-relatedfusiongenes,detectingcommonandnovelfusions
- FromRNAtoresultsin4daysincludingon-instrumentsoftwarethatdisplaysfusioncalls
- Compatibilitywithdesktopsequencerstomaximizelabbudgets
- OptimizedRNAsequencingforallsampletypes,includingFFPEtissues
SimpleFusionReportforCustomersNewtoNGS
On-instrumentfusioncallingprovidesNGS-basedfusiondetectiontolabswithoutadditionalbioinformaticssupport.Theanalysisprovidesalistofdetectedfusions,relevantdiseaseassociations(asidentifiedbytheMitelmandatabase),andevidenceoffusion-supportingreads.
Robust,ReproducIBLe,andLow-InputFusionAssay
Thisassayaccommodatesaslittleinputas20ngFFPERNAor10ngfresh-frozentotalRNA.TheTruSightRNAFusionPanelprovidesasensitive,reproducible,andeconomicalsolutionforstudiesofgenefusionsincancerresearch.
Specifications:
AssayTime | 2.5days |
Hands-OnTime | 11hours |
InputQuantity | 10ngtotalRNA,20–100ngFFPERNA |
SystemCompatibility | MiSeq,NextSeq550,MiSeqDxinResearchMode,MiniSeq,NextSeq500 |
Method | TargetedRNASequencing,SequencingforCytogenomics |
VariantClass | GeneFusions |
SpecializedSampleTypes | FFPE,LowInput |
Technology | Sequencing |
SpeciesCategory | Human |
CancerType | Pan-Cancer |